Last reviewed · How we verify
pregabalin and celecoxib
Pregabalin and celecoxib, marketed by Viatris Inc., is a combination therapy leveraging the mechanisms of both drugs to address pain management, positioning it in a competitive but significant market segment. A key strength is the extended market exclusivity until 2028, protected by a key composition patent, which provides a strong barrier to generic competition. The primary risk is the intense competition from other pain management therapies, which could erode market share and revenue.
At a glance
| Generic name | pregabalin and celecoxib |
|---|---|
| Sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Opioid-Free Pain Protocol After Shoulder Arthroplasty (PHASE4)
- Efficacy and Safety of Intravenous Dexamethasone Palmitate Treatments in Acute and Subacute Herpes Zoster Pain (NA)
- The Effect of Multimodal Pain Regimen on Use of Narcotics After Rotator Cuff Tear Repair (PHASE4)
- Clinical Efficacy and Safety of Tender Point Infiltration (TPI) for Acute and Subacute Zoster Associated Pain (NA)
- Multimodal Imaging and Biospecimen Collection for Low Back Pain (LBPB)
- Efficacy and Safety in the Combination of Celecoxib / Pregabalin / Vitamin B for Low Back Chronic Pain (PHASE3)
- SMART Embedded Intervention for Military Postsurgical Engagement Readiness (NA)
- Pre vs Post Block in Total Knee Arthroplasty (TKA) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: